MoonLake Immunotherapeutics(MLTX)
ZUG, SwitzerlandBiotechnology
Focus: MoonLake is a newly public (2024) Swiss biotech focused on tri-specific nanobody therapeutics, currently in clinical development across dermatology and rheumatology indications with a lean 51-200 person team.
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Employees
51-200
Open Jobs
11+11 this month
Growing — net +11 jobs in 30d
11 jobs added vs 0 removed. Steady team buildout.
Should You Work at MoonLake Immunotherapeutics?
AI assessmentBest suited for early-career scientists or specialists willing to join a lean clinical-stage biotech betting on a single program; limited for those seeking established career infrastructure or immediate promotion pathways.
Why Work Here
- Concentrated focus on one well-advanced clinical program (Sonelokimab) with 7 Phase 3 trials across two high-value indications—provides clear visibility into near-term value creation
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
7 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Sonelokimab
Relative BioequivalenceClinical Trials (1)
NCT06994936An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector
Phase 1Help build intelligence for MoonLake Immunotherapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.